Pharming (PHAR) Non Operating Interest Expenses (2020 - 2023)

Pharming's Non Operating Interest Expenses history runs 4 years deep, the most recent figure standing at -$7.8 million for Q3 2023.

• Quarterly Non Operating Interest Expenses fell 753.17% year-over-year to -$7.8 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was -$9.5 million (down 476.45% YoY) and the FY2021 annual result came in at $8511.1, up 126.19% from the prior year.
• Non Operating Interest Expenses was -$7.8 million for Q3 2023 at Pharming, down from $1.2 million in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $1.2 million in Q3 2022 and bottomed at -$29.6 million in Q3 2020.
• A 4-year average of -$6.5 million and a median of -$1.4 million in 2021 frame the typical range for Non Operating Interest Expenses.
• Annual changes were most pronounced in 2022 — Non Operating Interest Expenses surged 141.48% — and 2023, when it slumped 753.17%.
• Pharming's Non Operating Interest Expenses stood at $34756.4 in 2020, then tumbled by 82.8% to $5977.2 in 2021, then soared by 19942.67% to $1.2 million in 2022, then slumped by 753.17% to -$7.8 million in 2023.
• Business Quant data shows PHAR's Non Operating Interest Expenses at -$7.8 million in Q3 2023, $1.2 million in Q3 2022, and $5977.2 in Q4 2021.